Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2023 Earnings Conference Call May 24, 2023 8:30 AM ET
Company Participants
Vishwas Seshadri - Chief Executive Officer
Joseph Vazzano - Chief Financial Officer
Dmitriy Grachev - Chief Medical Officer
Brian Kevany - Chief Technical Officer, Head of Research
Madhav Vasanthavada - Vice President, Business Development
Greg Gin - Vice President, Investor Relations and Corporate Communications
Conference Call Participants
Maury Raycroft - Jefferies
Kristen Kluska - Cantor Fitzgerald
James Molloy - A.G.P./Alliance Global Partners
Operator
Greetings. Welcome to the Abeona Therapeutics First Quarter '23 Portfolio Update Conference Call. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to your host, Greg Gin, Vice President of Investor Relations and Corporate Communications. You may begin.
Greg Gin
Thank you, Holly. Good morning, everyone. I would like to welcome and thank everyone for joining us on our portfolio update conference call.
Our objective today is to share additional new positive data from our EB-101 and AAV ophthalmology programs recently presented at scientific congresses. The press release is announcing the data at the ISID and ASGCT meetings are available on our website at www.abeonatherapeutics.com.
Before we start, I would like to note that remarks made during today's call may contain projections and forward-looking statements. Forward-looking statements are made pursuant to the Safe Harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and are subject to change, and actual results may differ materially from those expressed or implied in the forward-looking statements.
Various factors that could cause actual results to differ include, but are not limited to, those identified under the Risk Factors section in our Form 10-K and periodic reports filed with the SEC. These documents are available on our website at www.abeonatherapeutics.com.
On the call today are Dr. Vish Seshadri, Chief Executive Officer, who will give some opening remarks. Dr. Dmitriy Grachev, Chief Medical Officer, who will review the new VIITAL study data that we presented at ISID; and Dr. Brian Kevany, Chief Technical Officer, who will review the animal proof-of-concept data from our AAV ophthalmology program presented at ASGCT last week. After the prepared remarks, joining us for the Q&A session will be Joe Vazzano, Chief Financial Officer; and Dr. Madhav Vasanthavada, Vice President, Business Development.
And with that, I will now turn the call over to Vish Seshadri to kick it off. Vish?